AIM
ANAB icon

Aigen Investment Management’s AnaptysBio ANAB Stock Holding History

Aigen Investment Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,450
Closed -$198K – 770
2020
Q3 		$198K Buy
+13,450
New +$243K 0.03% 652

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Aigen Investment Management's ANAB Position: Q4 2020 in Review

Aigen Investment Management sold out of AnaptysBio (ANAB) in Q4 2020, closing a stake of 13,450 shares — an estimated $198K sold.

Aigen Investment Management first reported a position in ANAB in Q3 2020 and held it in 1 quarter. The position peaked at $198K in Q3 2020. 136 funds tracked by Wall St. Rank hold ANAB as of Q4 2020.

  • Aigen Investment Management reported no remaining AnaptysBio position as of Q4 2020 after selling out during the quarter.
  • Aigen Investment Management sold 13,450 AnaptysBio shares in Q4 2020, an estimated $198K.
  • Aigen Investment Management first reported a position in AnaptysBio in Q3 2020 and held it in 1 quarter.
  • Aigen Investment Management's AnaptysBio position peaked at $198K in Q3 2020.
  • 136 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2020.

Based on Aigen Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.